# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-17T15:57:34.000000
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 13298 in / 4906 out
**Response SHA256:** 4cdb4fa77bf73559

---

## Referee Report: “Minimum Wages and Medicaid's Invisible Workforce: Provider Supply Responses to Labor Cost Shocks”

### Summary and contribution
The paper studies whether state minimum wage increases (2018–2024) affect Medicaid HCBS provider supply, using newly released provider-level T‑MSIS “Provider Spending” claims data linked to NPPES. The authors aggregate to a state-year panel (51 units × 7 years) and estimate effects using Callaway & Sant’Anna (2021) DiD with never-treated states as the primary control group. The main result is a negative effect on the log number of HCBS providers (ATT ≈ −0.161, p=0.069), growing in magnitude over event time; placebo outcomes on non-HCBS providers are null.

This is a potentially important policy interaction: labor market regulation interacting with administratively set Medicaid reimbursement rates. The data source is genuinely novel and, if validated and presented carefully, could be field-shaping.

That said, several issues—some conceptual/measurement, some econometric/inference-related—currently prevent the paper from meeting “top general-interest” standards. I view the project as *promising but not yet publishable*; a major revision could get it there.

---

# 1. FORMAT CHECK

### Length
- **Appears to be ~25–35 pages in compiled form**, but exact length is hard to infer from LaTeX source because tables/figures are external `\input{}` and `\includegraphics{}`. Likely meets the “25 pages excluding references/appendix” bar, but please verify in the compiled PDF.

### References
- The text cites several key works (Card & Krueger; Cengiz et al.; Callaway & Sant’Anna; Goodman-Bacon; Sun & Abraham; Rambachan & Roth), plus Medicaid/HCBS background.
- **However, the bibliography is not visible in the source provided** (`\bibliography{references}`), so I cannot confirm coverage or accuracy. See Section 4 below for specific additions that should be included.

### Prose
- Major sections (Introduction, Institutional Background, Results, Discussion, Conclusion) are written in paragraphs, not bullets. Good.

### Section depth
- Most major sections have ≥3 substantive paragraphs.
- **Conceptual framework** is very short and reads like a sketch; it likely needs more depth (e.g., mapping to observable outcomes and clarifying what “provider exit” means in claims/NPI terms).

### Figures
- Figures are included via `\includegraphics`. I cannot visually verify axes/data. You do provide captions/notes, which is good. (Per your instructions: I will not claim figures are missing/broken.)

### Tables
- Tables are `\input{tables/...}`; I cannot see whether they contain real numbers. The main text *reports* point estimates/SEs/p-values, which is encouraging.

**Fixable format items to address**
1. Ensure the compiled paper clearly reports N, number of treated states contributing to each estimand, and number of clusters for each table/figure.
2. Ensure each main table has a complete note: data sources, unit of observation, clustering, weights, and estimand definition.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **PASS** in the narrative: the main results quote SEs (e.g., −0.161 (SE 0.088)). Event study notes mention 95% CIs.
- But: I cannot confirm every coefficient in every table has SEs because tables are external.

**Action:** In every regression/event-study table, present coefficients with SEs in parentheses, and add 95% CIs for headline effects (see below).

### (b) Significance testing
- **PASS**: p-values reported; joint pre-trend test described.

### (c) Confidence intervals
- Event-study figures mention 95% CIs; but **the main “headline” ATT in Table 3 should also show a 95% CI** (not just p-values).
- With only ~30 clusters (9 treated + 21 control in baseline CS), inference can be sensitive; CIs should be prominent.

**Action:** Report 95% CIs for:
1. Overall ATT (primary outcome),
2. Key dynamic effects (e=1, e=3, e=5),
3. Placebo outcome.

Also consider wild cluster bootstrap CIs or randomization inference (see below).

### (d) Sample sizes
- You state the panel is 357 state-year observations, but **each estimator effectively uses fewer observations/cohorts** (since 2018-treated excluded from CS).
- **N (state-years), number of states, treated states, and cohorts should be reported for each specification**, including robustness tables.

**Action:** In each table: report (i) number of states, (ii) number treated contributing, (iii) cohorts, (iv) state-years used.

### (e) DiD with staggered adoption
- **PASS in principle**: you use Callaway & Sant’Anna (2021) and also mention Sun–Abraham.
- However, there is an *important implementation/interpretation concern*: because the panel starts in 2018, the CS analysis drops the large 2018-treated group (21 states). That means the “treated” sample for the preferred estimator is **only 9 states** in 4 cohorts.
  - This is not necessarily wrong, but it *radically changes the estimand* relative to “effects of minimum wage increases generally.”
  - It also raises power and external validity concerns: results may be driven by a small, selected set of “late” increasers.

**Action:** Make this limitation front-and-center and address it more rigorously. See Section 3 for identification threats and Section 6 for concrete suggestions (e.g., alternative designs that reincorporate 2018-treated states).

### (f) RDD
- Not applicable.

### Additional inference concerns (important)
1. **Few clusters / clustered inference reliability.** With ~30 clusters and only 9 treated, cluster-robust asymptotics may be shaky; p=0.069 is right in the range where inference method choices can flip conclusions.
   - **Action:** Add wild cluster bootstrap (Cameron, Gelbach & Miller style) p-values/CIs; and/or randomization inference using placebo treatment assignment among eligible states.
2. **Serial correlation / aggregation.** You use annual data with 7 periods; DiD standard errors can be sensitive with few time periods. CS handles some issues, but you should explicitly address serial correlation and show robustness (e.g., block bootstrap at state level over time).
3. **Event-study support varies by event time.** You acknowledge e=4,5 rely mainly on early cohorts. This should be formalized: provide a table showing which cohorts contribute to each event time and the effective sample size/weights.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
The design is plausible, and using never-treated states helps. But several threats remain serious:

## 3.1 Treatment definition and intensity
- Treatment is defined as “first minimum wage increase during sample period,” but many treated states have **multiple increases** and varying magnitudes. The “first increase” dummy may conflate:
  - small vs. large changes,
  - indexed vs. legislated changes,
  - anticipated multi-year schedules (common in minimum wage policy).

**Action:** Strengthen the design by focusing on intensity:
- Use **continuous treatment** as primary (e.g., log minimum wage, or Δ log min wage), and interpret as elasticity or semi-elasticity.
- Or define treatment as crossing salient thresholds (e.g., ≥$12, ≥$15), pre-registered or institutionally motivated.
- Show results scaled per $1 increase or 10% increase.

## 3.2 Parallel trends: evidence is necessary but not sufficient
- You report a pre-trend test p=0.324 and visually “close to zero.” That’s helpful, but:
  - With only 7 years and only 9 treated states, **power to detect pre-trends is limited**.
  - The treated states are geographically/politically clustered (you note this), so differential trends could exist.

**Action:** Add stronger diagnostics:
- Report **state-specific pre-trend slopes** (e.g., estimate pre-period trends and show treated vs control distribution).
- Add **covariate-adjusted CS** (Callaway & Sant’Anna allow covariates): unemployment rate, GDP growth, Medicaid enrollment, share elderly/disabled, COVID intensity, etc.
- Provide **donut-type robustness** around 2020–2021 given COVID disruptions (e.g., drop 2020 or interact COVID shock indicators with region).

## 3.3 Major confounder: ARPA HCBS FMAP bump and state HCBS investments
You mention ARPA Section 9817 (2021–2024) and say you “address this in robustness,” but I do not see a clear, convincing strategy in the main text. This is central because:
- ARPA funds were explicitly used for **workforce, provider rates, bonuses, capacity**—exactly your outcomes.
- States that raise minimum wages may also be the ones that more aggressively deployed ARPA funds or raised rates.

**Action:** At minimum:
- Include controls for **ARPA HCBS spending plans** or proxies (e.g., whether the state adopted and amount allocated; MACPAC/KFF summaries; timing of SPA approvals).
- Add an interaction: treatment × post-2021, or allow separate trends 2018–2019, 2019–2021, 2021–2024.
- Show results **excluding 2021–2024** (pre-ARPA) if feasible, acknowledging reduced post periods.

## 3.4 Measurement/construct validity: what is “provider supply” in T‑MSIS?
The outcome is “unique billing NPIs with ≥1 HCBS claim in a year.” This is a useful proxy, but it may reflect:
- billing consolidation (agencies absorbing independents),
- managed care encounter reporting changes,
- provider identifier changes, mergers, re-enumeration,
- changes in claim suppression rules (“<12 claims suppressed”) interacting with provider size.

**Action (critical):**
1. Show that results hold for **alternative supply measures**:
   - total number of HCBS claims,
   - total beneficiaries served (you have “unique beneficiaries” at row level),
   - total paid amount (already included but imprecise),
   - intensive margin measures: spending per provider, beneficiaries per provider.
2. Show robustness to **threshold definitions** of “active provider” (≥12 claims, ≥50 claims, ≥$X paid), to address suppression and tiny providers.
3. Separate **organizational vs individual NPIs** (you already have entity type). If minimum wage binds mainly for agency-employed workers, the effect might appear differently in org vs individual billing.

## 3.5 Placebo/falsification
The placebo on non-HCBS providers is a real strength. But the placebo group may still be affected indirectly by state-level changes (e.g., healthcare system changes) and may not be comparable.

**Action:** Add additional falsifications:
- Outcomes that should move in the *opposite* direction under retention (e.g., provider churn/turnover proxy if measurable).
- Sectors within Medicaid likely unaffected by minimum wage (e.g., physician NPIs by taxonomy), *and* sectors plausibly affected (e.g., DME suppliers), to show specificity.

### Do conclusions follow from evidence?
- The policy narrative (“minimum wages reduce supply due to fixed reimbursement”) is plausible.
- But the paper currently goes beyond what is cleanly identified by asserting mechanism dominance (cost-push vs retention) without directly observing wages, margins, or rates.

**Action:** Tone down mechanism claims or add mechanism evidence (see Section 6).

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

You cite many essentials, but several key references are either missing or should be explicitly engaged given your claims about fixed prices, pass-through, and minimum-wage incidence in regulated sectors.

## 4.1 Minimum wage: canonical recent methods and synthesis
You cite Cengiz et al. and Manning; add:
- Dube (2019) review on localized controls and design issues.
- Neumark & Wascher (2007) as classic skeptical view (you should engage it even if you disagree).
- Allegretto, Dube, Reich, Zipperer (2017) on credibility/design.

```bibtex
@article{Dube2019,
  author  = {Dube, Arindrajit},
  title   = {Impacts of Minimum Wages: Review of the International Evidence},
  journal = {Independent Report},
  year    = {2019}
}

@article{NeumarkWascher2007,
  author  = {Neumark, David and Wascher, William},
  title   = {Minimum Wages and Employment},
  journal = {Foundations and Trends in Microeconomics},
  year    = {2007},
  volume  = {3},
  number  = {1--2},
  pages   = {1--182}
}

@article{AllegrettoEtAl2017,
  author  = {Allegretto, Sylvia and Dube, Arindrajit and Reich, Michael and Zipperer, Ben},
  title   = {Credible Research Designs for Minimum Wage Studies},
  journal = {ILR Review},
  year    = {2017},
  volume  = {70},
  number  = {3},
  pages   = {559--592}
}
```

## 4.2 Pass-through and regulated prices (very relevant to “cannot raise prices” claim)
The “fixed reimbursement” mechanism is essentially a pass-through/incidence argument under price regulation. Consider adding:
- Ashenfelter & Card (1982)-style incidence is too old; more relevant is regulated healthcare price literature and pass-through.
- For Medicaid specifically, work on **Medicaid fee changes and provider participation** (you cite Finkelstein 2007; add others).

Examples:
- Currie, Gruber, Fischer (various) on Medicaid physician fees and participation.
- Kaiser Family Foundation / MACPAC empirical work isn’t “top-journal,” but you can cite for institutional facts; pair with peer-reviewed evidence.

One strong peer-reviewed example:
```bibtex
@article{AlexanderCurrie2021,
  author  = {Alexander, Diane and Currie, Janet},
  title   = {The Effects of Medicaid on Access to Care and Health Outcomes},
  journal = {Journal of Economic Literature},
  year    = {2021},
  volume  = {59},
  number  = {2},
  pages   = {521--586}
}
```
(If you already cite it, ensure it’s in the bib.)

And on physician fees / participation:
```bibtex
@article{Decker2012,
  author  = {Decker, Sandra L.},
  title   = {In 2011 Nearly One-Third of Physicians Said They Would Not Accept New Medicaid Patients, but Rising Fees May Help},
  journal = {Health Affairs},
  year    = {2012},
  volume  = {31},
  number  = {8},
  pages   = {1673--1679}
}
```
(Health Affairs is policy-facing, but relevant for the institutional link between payment and participation.)

## 4.3 Staggered DiD: additional practitioner references
You cite Goodman-Bacon, Roth et al., Baker et al. Consider also:
- Borusyak, Jaravel, Spiess (imputation estimator).
- de Chaisemartin & D’Haultfœuille (TWFE pitfalls and alternatives).

```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint},
  year    = {2021}
}

@article{deChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

## 4.4 HCBS / direct care empirical economics
You cite PHI and MACPAC reports. Add peer-reviewed work on home care labor markets and reimbursement, e.g.:
- Studies on Medicaid home care wage pass-through and labor supply/turnover (there is a health economics literature here).

I cannot safely supply exact BibTeX for specific niche papers without risking inaccuracies; but I strongly recommend you add at least 3–5 peer-reviewed HCBS workforce papers (Health Economics, JHE, Health Affairs, etc.) that directly study reimbursement/wages/turnover in home care.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- **PASS**: major sections are paragraph-based.

### Narrative flow
- The introduction is strong: big policy market, clear mechanism tension (cost-push vs retention), and a crisp empirical plan.
- One issue: the narrative currently oversells the “first comprehensive provider-level claims data” contribution without sufficiently addressing **what T‑MSIS Provider Spending does and does not measure**, and what biases might arise from using “billing NPIs” as “supply.”

### Sentence quality / accessibility
- Generally clear and readable for a general-interest audience.
- A few claims should be tightened:
  - “HCBS represent \$1.09 trillion in Medicaid spending” reads like *total Medicaid spending in the file*, not “HCBS.” Later you say T/H/S codes are 52% of total spending. Please ensure consistency: is \$1.09T total Medicaid payments in the file, not HCBS?
  - “Until February 2026, provider-level Medicaid claims data did not exist in the public domain” is plausible but should be phrased more cautiously and precisely (there are other Medicaid data products; the novelty is national provider-claim linkage at scale).

### Tables and self-containment
- Because tables are external, I can’t judge formatting. For top journals, main tables must be self-explanatory with full notes and clear estimands.

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE IT MORE IMPACTFUL)

## 6.1 Reincorporate 2018-treated states into a credible main design
Right now, your “preferred” CS design estimates effects for only 9 treated states. You need a plan for the 21 states treated in 2018 (a huge share of the policy-relevant cases).

Options:
1. **Use earlier pre-period data for outcomes**: Can T‑MSIS be extended pre-2018 via other releases? If not, can you construct a consistent pre-2018 provider measure from another dataset (e.g., NPPES + Medicaid enrollment/provider registry proxies)? Even a noisier pre-period could help define baseline for 2018 cohort.
2. **Redefine treatment** to later “large” increases occurring after 2018 (e.g., first increase ≥$0.50 or ≥5%).
3. **Adopt an estimator that can use all treated units with limited pre-periods**, but then be explicit about identifying assumptions. (Even then, you need credible pre-trends; with only 2018–2024, this is hard.)

At minimum, separate the contribution into:
- a clean CS estimate for late adopters (your current design),
- plus a carefully caveated broader estimate using alternative methods.

## 6.2 Mechanism: link minimum wage bites and Medicaid reimbursement
The central mechanism is “rate-cost squeeze.” Make this testable:
- Construct a **minimum wage bite** measure: min wage / median aide wage (BLS OES), or min wage relative to state HCBS reimbursement for key codes (T1019).
- Construct a **Medicaid rate generosity** measure (MACPAC has state comparisons; also KFF state rate surveys).
- Estimate heterogeneous effects: larger negative effects where bite is high and rates are low.

This would elevate the paper from “reduced form fact” to “policy mechanism with clear predictions.”

## 6.3 Use outcomes that better capture capacity/access
Provider counts are informative but not directly access.
If you can, add:
- beneficiaries served (from T‑MSIS unique beneficiaries field),
- claims volume,
- spending per beneficiary,
- churn (entry/exit) and not just levels.

If beneficiaries served stays flat while provider counts fall, the welfare story changes (consolidation rather than access loss).

## 6.4 Address reporting/suppression and data artifacts head-on
Given suppression for rows with <12 claims:
- show robustness to defining “active provider” using thresholds above suppression,
- show that treated states do not differentially experience suppression-related mechanical drops.

## 6.5 Stronger inference
Given the marginal p-value:
- add wild cluster bootstrap,
- consider randomization inference assigning “placebo adoption years” within region strata,
- report minimum detectable effects to contextualize power.

## 6.6 Framing improvements
- Clarify whether the policy implication is “minimum wage increases are bad” versus “they require coordinated Medicaid rate adjustments.” The latter is more policy-relevant and consistent with your own discussion.
- Be explicit about **general equilibrium**: providers may shift to private-pay markets, agencies may merge, etc.

---

# 7. OVERALL ASSESSMENT

### Key strengths
1. **Novel data** with national scope and provider identifiers; high potential value to the profession.
2. **Appropriate modern DiD tools** (CS; Sun–Abraham) and explicit awareness of TWFE pitfalls.
3. **Compelling policy question** with clear institutional channel (fixed reimbursement).
4. **Good placebo design** (non-HCBS providers) that supports specificity.

### Critical weaknesses (must address)
1. **Preferred identification relies on only 9 treated states** because 2018-treated states are dropped. This sharply limits external validity and raises concerns about selection and power.
2. **Mechanism not directly tested**: you infer “cost-push dominates,” but do not link effects to reimbursement rigidity, rate changes, or wage bite.
3. **Inference fragility**: with few treated states and clustered SEs, the headline result is marginal; additional inference methods are needed.
4. **Outcome validity**: “active billing NPI count” may not equal “provider supply/capacity”; must show robustness to alternative capacity measures and definitions.

### Specific path to improvement
- Rework the empirical section around (i) a richer set of supply/capacity outcomes, (ii) heterogeneity by bite/rates, (iii) stronger inference, and (iv) a transparent, credible approach to the 2018 cohort problem.

DECISION: MAJOR REVISION